**國軍高雄總醫院左營分院放射腫瘤科**

**2023年鼻咽癌放射治療指引**

本版放射腫瘤科共識會議日期：2016年4月15日，本版定案日期：2016年4月29日，

本版修訂日期：2023年6月15日(與國軍高雄總醫院放射腫瘤科崔樂平主任)

期別依據：AJCC 8thedition(2017)

鼻咽癌放射治療指引與監測修正對照表

|  |  |  |
| --- | --- | --- |
| 2022 | 2023 | 說明 |
| 經常做頸部柔軟運動 | 經常做頸部柔軟運動及手部按摩 | 修改 |
|  | 更新 references | 補充 |

常見放射治療適應症

* 1. 根治性目的(curative intent):
  2. 首次根治性治療:
     + 1. 放射治療:T1N0M0
       2. 放射治療加化學治療:T1N1-3M0;T2-4NanyM0

2. Any T, Any N, with early M1

1. 先化學治療，後放射治療或合併化學治療。
2. 同步化學及放射治療（適合遠端轉移病灶不大或為局限性，或是有明顯鼻咽或頸部局部症狀）。

3. 局部區域(locoregional)復發且無遠端轉移病灶。

1. 緩解性目的(palliative intent)
   1. 明顯骨等遠端轉移病灶
   2. 併有遠端轉移且產生症狀之局部復發

**根治性放射治療必要流程**

一、治療計劃前完整的臨床評估

1. 確認期別及病理報告。
2. 必要檢查以排除全身多處轉移可能(考慮電腦斷層正子攝影)。
3. 經團隊會議討論或相關科別照會。
4. 必要時會做放射治療前的牙科會診及牙齒處置。

二、治療體位設定

1. 病人採仰臥，雙手置於身旁。以頭頸模具固定，治療標記設定於模具上。

三、模擬攝影

1. 病人依設定體位躺上電腦斷層攝影床，必要時以金屬線進行標記(如腫大之頸部淋巴)，並配合模具固定身體位置。

1. 通常電腦斷層掃描每切面間距為2.5mm，掃描範圍應至少包括眼眶及鎖骨下緣。
2. 掃描後應以油性水洗不掉簽字筆作好標記供治療辨認。

四、治療計劃(treatment planning)--

1. 放療劑量：
2. 原發(鼻咽)及侵犯淋巴部位/淋巴區給予70-76Gy(1.8-2 Gy/fx)

ii. 潛在風險部位/淋巴區44-63Gy(1.8-2 Gy/fx)  
建議分高，中，低危險區域做三階段不同劑量治療。

Sequential IMRT technique:deliver the initial phase (week 4-5) followed by moderate-dose boost volume phase (week 5-6.5),

then gross tumor boost to high dose (week 6.5 to 8), usually using 3 separate dose plans

Examples:

Three phases:

CTV-H:primarytumorand involved nodal area:

70.2Gy/39fx–75.6Gy/42fx

CTV-M: primary tumor with 1.5-2.0 cm margin (high risk subclinical region)/

involved node with 1.0-1.5 cm margin or involved nodal level (high risk subclinical region) :

57.6 Gy/ 32 fx– 61.2 Gy/ 34 fx

CTV-L:uninvolved nodal area:

43.2Gy/24fx- 50.4Gy/28fx

1. 採用IMRT為治療方式，以減少危急器官放射劑量。
2. CTV 包括原發腫瘤部位、侵犯淋巴部位/淋巴區以及潛在風險淋巴區。
3. 治療計劃標靶體積(PTV: planning target volume)：PTV依CTV增加0.3至0.5公分。鄰近腦幹處，考慮器官忍受劑量可為0.1公分
4. 劑量評估參數：至少包括腦幹、脊髓、腮腺、顳下頜關節、眼睛(水晶體)、視神經，視交叉等劑量。

五、放射治療前評估紀錄：包括病理報告、期別、核磁共振或電腦斷層攝影影像報告、病人簡史、理學檢查、重要檢查結果、診斷評估、體能狀態及治療計劃。

六、首次治療前應使用定位照相驗證片以確保照射範圍正確性，並由主治醫師確認簽章後才能進行。

**重要器官劑量評估參數**

NOTE: All dose constraints below should be met whether the patient undergoes 3D-CRT or IMRT techniques.

Critical Normal Structures

Dose constraints are given below:

Structure true structure constraint PRV constraint

Brainstem 54 Gy max dose no more than 1% to exceed 60 Gy

Spinal Cord 45 Gy max dose no more than 1% to exceed 50 Gy

Optic Nerves,Chiasma54Gy max dose 54 Gy max dose

Mandible, TM joint 70 Gy, if not possible then nomore than 1cc to exceed 75 Gy

Parotid glands: Mean dose <26 Gy (optimal) or 30 Gy(acceptable), should be achieved in at least one gland; or at least 50% of one gland will receive < 33 Gy (optimal) or 35Gy(acceptable) (should be achieved in at least one gland).

Other normal structures can be considered:

Each cochlea No more than 5% receives 55 Gy or more

Eyes Max dose less than 50 Gy

Lens Max dose less than 10Gy

Glottic Larynx Mean dose less than 40Gy

Esophagus, Postcricoid pharynx Mean dose less than 45 Gy

**根治性鼻咽癌放射治療可能副作用與處置:**

* 1. 急性副作用：

1.口腔黏膜炎：常以溫開水漱口，嚴重時可請醫師處方漱口劑及藥膏。

2.嗅覺味覺遲鈍：需配合調節食物口味，在治療後將漸漸恢復。

3.皮膚炎: 減少磨擦，嚴重時可請醫師處方藥膏。

4.口乾: 隨身攜帶水壺漱口或飲用。

5.下巴、頸部淋巴水腫：嚴重時可請醫師處理或開處方藥物。

6.短暫性脊髓病變：在治療後將漸漸恢復。

二、慢性副作用：

1.口乾: 隨身攜帶水壺漱口或飲用，嚴重時可請醫師處方藥物。

2.蛀牙: 保持口腔清潔，定期牙科門診防治。

3.牙關緊閉: 練習張口運動。

4.頸部僵硬: 經常做頸部柔軟運動及手部按摩。

5.中耳炎及聽力減退: 定期耳鼻喉科門診追蹤。

6.少數零星個案且較嚴重的副作用，如腦組織壞死、視神經及視網膜病變、腦幹病變、腦下垂體功能低下、永久性脊髓病變、

骨頭壞死、白內障、吞嚥困難、大量出血及中風等等：定期門診追蹤，嚴重時可考慮介入處置。

**根治性鼻咽癌放射治療常見之副作用及程度分級:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **CTCAE 4.03-June 14, 2010** | | | | | |
|  | **Grade** | | | | |
| **Adverse event** | **1** | **2** | **3** | **4** | **5** |
| Oral pain | Mild pain | Moderate pain; limiting  Instrumental ADL | Severe pain; limiting self care ADL | - | - |
| Definition: A disorder characterized by a sensation of marked discomfort in the mouth, tongue or lips | | | | | |
| Mucositis oral | Asymptomatic or mild symptoms; intervention nor indicated | Moderate pain; not interfering with oral intake; modified diet indicated | Severe pain; interfering with oral intake | Life-threatening consequences; urgent intervention indicated | death |
| Definition: A disorder characterized by inflammation of the oral mucosal | | | | | |
| Dry mouth | Symptomatic(e.g., dry or thick saliva) without significant dietary alteration; unstimulated saliva flow>0.2ml/min | Moderate symptoms; oral intake alteration(e.g., copious water, other lubricants, diet limited to purees and/or soft, moist foods); unstimulated saliva 0.1-0.2 ml/min | Inability to adequately aliment orally; tube feeding or TPN indicated; unstimulated saliva <0.1 ml/min | - | - |
| Definition: A disorder characterized by reduced salivary flow in the oral cavity | | | | | |
| Dysphagia | Symptomatic, able to eat regular diet | Symptomatic and altered eating/swallowing | Severely altered eating/swallowing; tube feeding or TPN or hospitalization indicated | Life-Threatening consequences; urgent intervention indicated | Death |
| Definition: A disorder characterized by difficulty in swallowing | | | | | |
| Dermatitis radiation | Faint erythema or dry desquamation | Moderate to brisk erythema; patchy moist desquamation, mostly confined to skin folds and creases; moderate edema | Moist desquamation in areas other than skin folds and creases; bleeding induced by minor trauma or abrasion | Life-threatening consequences; skin necrosis or ulceration of full thickness dermis; spontaneous bleeding from involved site; skin graft indicated | Death |
| Definition: A finding of inflammatory reaction occurring as a result of exposure to biologically effective levels of ionizing radiation | | | | | |

**參考文獻:**

1. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Head and Neck cancersVersion: 2.2023.Available at https://www.nccn.org/professionals/physician\_gls/pdf/head-and-neck.pdf. Accessed June 7, 2023.
2. Chan ATC, Gregoire V, Lefebvre JL, Licitra L, Felip E. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical practice guidelines for

diagnosis, treatment and follow-up. Annals of oncology 2010;21: 187-189

1. Al-Sarraf M, at el. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup

study 0099. J ClinOncol 1998;16: 1310-1317

1. Chan ATC, et al. Concurrent Chemotherapy-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: Progression-Free Survival Analysis of a Phase III Randomized Trial. J ClinOncol 2002; 20:2038-2044
2. Wee J, et al. Randomized Trial of Radiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy in Patients With American Joint Committee on Cancer/International Union Against Cancer Stage III and IV Nasopharyngeal Cancer of the Endemic Variety. J ClinOncol 2005;23: 6730-6738
3. American Head and Neck Society Practical Guideline.
4. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience. Int J RadiatOncolBiol Phys. 2002;29:12-22
5. Kam MK, Leung SF, Zee B, et al. Impact of Intensity-modulated radiotherapy (IMRT) on salivary gland function in early-stage

nasopharyngeal carcinoma (NPC) patients. Proc Am SocClinOncol. 23: 500s, 2005.

1. Kam MK, Teo PM, Chau RM, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: The Hong Kong

experience. Int J RadiatOncolBiol Phys.1440-50, 2004.

1. Wolden SL, Chen WC, Pfister DG, et al. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: Update of the Memorial

Sloan-Kettering experience.Int J RadiatOncolBiol Phys.57-62, 2006

1. Langendijk JA, Leemans CR, Buter J., et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: A meta-analysis of the published literature. J ClinOncol. 4604-4612, 2004.
2. Lee AW, et al. Current Management of Nasopharyngeal Cancer. Semi RadiaOncol. 22 (2012):233-244
3. Gang P, et.al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional

two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma.RadiotOncol 104 (2012) 286–293

1. Lee AW, et al. The battle against nasopharyngeal cancer. RadiatOncol. 104 (2012) 272–278
2. CTCv4.0 <http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf>
3. Chen L,Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent

chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentrerandomised controlled trial. Lancet Oncol. 13(2):163-71, 2012

1. Jin X, Han C, Zhou Y, Yi J, Yan H, Xie C.[A modified VMAT adaptive radiotherapy for nasopharyngeal cancer patients based on CT-CT image fusion.](http://www.ncbi.nlm.nih.gov/pubmed/24279414)RadiatOncol. 27;8:27, 2013.
2. Miao J, Di M, Chen B, et al.[A Prospective 10-Year Observational Study of Reduction of Radiation Therapy Clinical Target Volume and Dose in Early-Stage Nasopharyngeal Carcinoma](https://www.redjournal.org/article/S0360-3016(20)30959-7/fulltext). Int J RadiatOncolBiol Phys. 2020;107;672-82.
3. Ng WT, Tung SY, Lee V, et al. Lee.[Concurrent-Adjuvant Chemoradiation Therapy for Stage III-IVB Nasopharyngeal Carcinoma—Exploration for Achieving Optimal 10-Year Therapeutic Ratio](https://www.redjournal.org/article/S0360-3016(18)30747-8/fulltext). Int J RadiatOncolBiol Phys. 2018;101;1078-86.
4. Sun LM, Li CI, Huang EY, Vaughan TL. [Survival differences by race in nasopharyngeal carcinoma.](https://pubmed.ncbi.nlm.nih.gov/17090616/)Am J Epidemiol. 2007;165(3):271-8.
5. Lee AW, Ng WT,Pan JJ, et al. [International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma](https://www-sciencedirect-com.autorpa.ndmctsgh.edu.tw/science/article/pii/S0167814017326865). RadiotherOncol. 2018;126;25-36.

**2023年鼻咽癌放射治療品質監測指標**

1. 根治性鼻咽癌病人接受放射治療前，主治醫師對該療程進行確認及簽章比率:閾值:95%以上

分子定義：監測期間內，因鼻咽癌進行根治性放射治療，於接受放射治療前，主治醫師對該病患療程進行確認及簽章之人數

分母定義：監測期間內，因鼻咽癌進行根治性放射治療總人數

1. 根治性鼻咽癌病人接受放射治療前，使用定位照相以確保照射範圍正確性之比率:閾值:90%

分子定義：監測期間內，因鼻咽癌進行根治性放射治療，於接受放射治療前，使用定位照相或影像導引以確保照射範圍正確性之人數

分母定義：監測期間內，因鼻咽癌進行根治性放射治療總人數

1. 根治性鼻咽癌病人接受放射治療時，劑量符合標準政策之比率:閾值:90%以上

分子定義：監測期間內，因鼻咽癌進行根治性放射治療，於療程完成時，總劑量與標準劑量誤差正負(含)10%以內之人數

分母定義：監測期間內，因鼻咽癌進行根治性放射治療總人數

4. 根治性鼻咽癌病人接受放射治療時，治療時間符合標準政策之比率:閾值:90%以上

分子定義：監測期間內，因鼻咽癌進行根治性放射治療，於療程完成時，總治療時間與標準治療時間誤差為正負(含)兩週以內之人數

分母定義：監測期間內，因鼻咽癌進行根治性放射治療總人數

5.根治性鼻咽癌病人接受放射治療時，治療次數符合標準政策之比率:閾值:90%以上

分子定義：監測期間內，因鼻咽癌進行根治性放射治療，於療程完成時，實際次數與標準次數誤差為正負(含)10%以內之人數

分母定義：監測期間內，因鼻咽癌進行根治性放射治療總人數

6.根治性鼻咽癌病人接受放射治療時，急性期非血液副作用出現第三級或以上之反應的比率:閾值:30 %

分子定義：監測期間內，因鼻咽癌進行根治性放射治療，於療程完成時，急性期副作用出現第三級或以上之反應之人數。

分母定義：監測期間內，因鼻咽癌進行根治性放射治療總人數